Revenue: As of FY2025, the actual value is USD 0.EPS: As of FY2025, the actual value is USD -2.27, missing the estimate of USD -1.975.EBIT: As of FY2025, the actual value is USD -179.32 M.Larimar Therapeutics, Inc. operates as a single, consolidated segment focused on life sciences, primarily the development of nomlabofusp, and has not generated any revenue from product sales to date, with no expectation of doing so in the foreseeable future.<h4>Operational Metrics</h4><ul><li>Net Loss: For the year ended December 31, 2025, the net loss was - $165.7 million, an increase in loss of - $85.1 million compared to - $80.6 million for the year ended December 31, 2024.</li><li>Total Operating Expenses: Total operating expenses increased by $81.6 million, reaching $172.5 million in 2025 from $90.9 million in 2024.<ul><li>Research and Development Expenses: These expenses rose by $80.9 million to $154.2 million in 2025 from $73.3 million in 2024, primarily due to a $63.3 million increase in nomlabofusp manufacturing costs, a $6.3 million increase in ongoing clinical studies costs, a $5.9 million increase in professional consulting fees, a $4.3 million increase in personnel expense, and a $2.1 million increase in non-clinical costs.</li><li>General and Administrative Expenses: These expenses increased by $0.7 million to $18.3 million in 2025 from $17.6 million in 2024, mainly driven by a $1.2 million increase in personnel expense and a $0.9 million increase in professional consulting fees, partially offset by a decrease in non-cash stock compensation expense.</li></ul></li><li>Loss from Operations: The loss from operations was - $172.5 million in 2025, an increase in loss of - $81.6 million compared to - $90.9 million in 2024.</li><li>Other Income, Net: Other income, net, decreased by - $3.5 million to $6.8 million in 2025 from $10.3 million in 2024, primarily due to lower interest yields and reduced average investable cash, cash equivalents, and marketable securities balances.</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities increased to - $113.2 million in 2025 from - $70.8 million in 2024.</li><li>Net Cash Provided by (Used in) Investing Activities: Investing activities provided $100.3 million in net cash in 2025, mainly from $184.0 million in maturities of marketable securities offset by $83.6 million in purchases, contrasting with - $85.4 million used in 2024 due to $227.9 million in purchases partially offset by $143.0 million in maturities.</li><li>Net Cash Provided by Financing Activities: Financing activities provided $65.1 million in cash in 2025, primarily from a common stock offering, compared to $161.9 million provided in 2024, also primarily from a common stock offering.</li></ul><h4>Unique Metrics</h4><ul><li>Cash, Cash Equivalents, and Marketable Securities: As of December 31, 2025, Larimar Therapeutics, Inc. held $136.9 million in cash, cash equivalents, and marketable securities.</li><li>Accumulated Deficit: The accumulated deficit was $434.8 million as of December 31, 2025.</li><li>February 2026 Public Offering: The company received net proceeds of approximately $107.6 million from a public offering of common stock in February 2026.</li></ul><h4>Outlook / Guidance</h4>Larimar Therapeutics, Inc. anticipates that its cash, cash equivalents, and marketable securities of $136.9 million as of December 31, 2025, combined with the $107.6 million net proceeds from the February 2026 public offering, will fund operations into the second quarter of 2027. The company plans to submit a Biologics License Application (BLA) seeking accelerated approval for nomlabofusp in June 2026 and expects to provide topline study data from its ongoing Open Label (OL) study in the second quarter of 2026. Enrollment screening for the global confirmatory Phase 3 study in the U.S. is planned for the second quarter of 2026, with the first patient dosing expected in mid-2026.

Larimar Therapeutics | 10-K: FY2025 Revenue: USD 0